An overview of the current landscape of available treatment options for Demodex blepharitis is analyzed.
This is a video synopsis/summary of a discussion involving Elizabeth Yeu, MD.
Yeu discusses how the recent FDA approval of lotilaner ophthalmic solution 0.25% (Xdemvy) finally provides an effective treatment for patients with Demodex blepharitis. Unlike past therapies, this clear solution dosed twice daily has superb efficacy alongside excellent safety and tolerability. In two combined studies, 50% of patients had a reduction of collarettes and 60% of patients had mites completely eradicated. Such substantial improvement was unprecedented. Additionally, the solution form is preferable to a blurring ointment that is hard to apply. Yeu is excited to have an excellent therapeutic option now. She can educate and empower patients about this new treatment, targeting the root cause of their condition.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More